Therapy for metastatic castration-resistant prostate cancer (mCRPC) has become more complex due to recent medical findings.
Today different options for first- and second-line treatment are available. Therefore scientific attention focuses on possible sequences and combinations. Besides, biomarkers play an important role as they can support therapeutic decisions and may enable more focused therapies. A new evaluation of biomarkers for advanced prostate cancer is necessary since the tumour biology is changing. One prognostic marker in mCRPC is PSA but this marker has to be interpreted with caution in this situation. Validated predictive markers for mCRPC are still lacking. In some studies potential predictive markers have been analysed.
Written by:
Miller K. Are you the author?
Reference: Aktuelle Urol. 2015 Jan;46(1):66-70.
doi: 10.1055/s-0034-1396859
PubMed Abstract
PMID: 25658233
Article in German.